<?xml version="1.0" encoding="UTF-8"?>
<collection xmlns="http://www.loc.gov/MARC21/slim">
 <record>
  <leader>     caa a22        4500</leader>
  <controlfield tag="001">469090642</controlfield>
  <controlfield tag="003">CHVBK</controlfield>
  <controlfield tag="005">20180323133016.0</controlfield>
  <controlfield tag="007">cr unu---uuuuu</controlfield>
  <controlfield tag="008">170328e19920601xx      s     000 0 eng  </controlfield>
  <datafield tag="024" ind1="7" ind2="0">
   <subfield code="a">10.1007/BF00464702</subfield>
   <subfield code="2">doi</subfield>
  </datafield>
  <datafield tag="035" ind1=" " ind2=" ">
   <subfield code="a">(NATIONALLICENCE)springer-10.1007/BF00464702</subfield>
  </datafield>
  <datafield tag="100" ind1="1" ind2=" ">
   <subfield code="a">Pettersson</subfield>
   <subfield code="D">I.</subfield>
   <subfield code="u">Department of Medical Cell Genetics, Medical Nobel Institutet, Karolinska Institutet, Box 60 400, S-104 01, Stockholm, Sweden</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="245" ind1="1" ind2="0">
   <subfield code="a">Methods of epitope mapping</subfield>
   <subfield code="h">[Elektronische Daten]</subfield>
   <subfield code="c">[I. Pettersson]</subfield>
  </datafield>
  <datafield tag="520" ind1="3" ind2=" ">
   <subfield code="a">Concluding remarks: It is important to remember that the merits of the different approaches to epitope mapping should be judged against the purpose of the study. A peptide specifically recognized by nearly all sera containing a certain autoimmune specificity [20, 21, 26], would most likely be selected for the detection of the anti-linear/continuous epitope fraction among those autoantibodies and could be highly useful for diagnostic purposes. This is true even if a majority of the antibodies were directed against conformational/discontinuous protein epitopes. If the purpose is to study the induction or maintenance of the autoimmune response, one would also have to look at and account for the conformation-dependent autoantibodies. There is also the possibility that some pathogenic autoantibodies could constitute a small fraction requiring the complete nucleic acid-protein complex as an antigen. In that case, the ‘pathogenic' epitope would not be identified nor mapped using the techniques discussed in this review.</subfield>
  </datafield>
  <datafield tag="540" ind1=" " ind2=" ">
   <subfield code="a">Kluwer Academic Publishers, 1992</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">autoantibody</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">autoantigen</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">B-cell epitope</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="773" ind1="0" ind2=" ">
   <subfield code="t">Molecular Biology Reports</subfield>
   <subfield code="d">Kluwer Academic Publishers</subfield>
   <subfield code="g">16/3(1992-06-01), 149-153</subfield>
   <subfield code="x">0301-4851</subfield>
   <subfield code="q">16:3&lt;149</subfield>
   <subfield code="1">1992</subfield>
   <subfield code="2">16</subfield>
   <subfield code="o">11033</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2="0">
   <subfield code="u">https://doi.org/10.1007/BF00464702</subfield>
   <subfield code="q">text/html</subfield>
   <subfield code="z">Onlinezugriff via DOI</subfield>
  </datafield>
  <datafield tag="908" ind1=" " ind2=" ">
   <subfield code="D">1</subfield>
   <subfield code="a">research-article</subfield>
   <subfield code="2">jats</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">856</subfield>
   <subfield code="E">40</subfield>
   <subfield code="u">https://doi.org/10.1007/BF00464702</subfield>
   <subfield code="q">text/html</subfield>
   <subfield code="z">Onlinezugriff via DOI</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">100</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Pettersson</subfield>
   <subfield code="D">I.</subfield>
   <subfield code="u">Department of Medical Cell Genetics, Medical Nobel Institutet, Karolinska Institutet, Box 60 400, S-104 01, Stockholm, Sweden</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">773</subfield>
   <subfield code="E">0-</subfield>
   <subfield code="t">Molecular Biology Reports</subfield>
   <subfield code="d">Kluwer Academic Publishers</subfield>
   <subfield code="g">16/3(1992-06-01), 149-153</subfield>
   <subfield code="x">0301-4851</subfield>
   <subfield code="q">16:3&lt;149</subfield>
   <subfield code="1">1992</subfield>
   <subfield code="2">16</subfield>
   <subfield code="o">11033</subfield>
  </datafield>
  <datafield tag="900" ind1=" " ind2="7">
   <subfield code="a">Metadata rights reserved</subfield>
   <subfield code="b">Springer special CC-BY-NC licence</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="898" ind1=" " ind2=" ">
   <subfield code="a">BK010053</subfield>
   <subfield code="b">XK010053</subfield>
   <subfield code="c">XK010000</subfield>
  </datafield>
  <datafield tag="949" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="F">NATIONALLICENCE</subfield>
   <subfield code="b">NL-springer</subfield>
  </datafield>
 </record>
</collection>
